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SUMMARY
We describe the management of a woman aged
52 years with molecularly conﬁrmed Sorsby fundus
dystrophy, who presented with acute visual deterioration
in her right eye. Fundus examination identiﬁed a right
macular lesion suggestive of a choroidal neovascular
membrane (CNVM). Optical coherence tomography
angiography (OCTA) conﬁrmed the presence of a CNVM.
She was treated with 2 monthly intravitreal injections of
bevacizumab, associated with OCTA evidence of
regression of the CNVM and improvement in her visual
acuity. OCTA is a novel, non-invasive method of imaging
the retinal vasculature. Images are acquired rapidly, with
no associated side effects, offering advantages over the
current gold standard technique—fundus ﬂuorescein
angiography.
BACKGROUND
To date, the use of optical coherence tomography
angiography (OCTA) has been reported in associ-
ation with several forms of retinopathy but thus far
not in inherited retinal disease (IRD).1–7 Sorsby
fundus dystrophy (SFD) is an autosomal dominant
retinopathy characterised by nyctalopia, commonly
in the fourth to ﬁfth decade, followed shortly
thereafter by the loss of central vision as a result of
macular atrophy or choroidal neovascularisation.8–11
Earlier, there was no effective treatment for chor-
oidal neovascular membrane (CNVM).12–14 Since
the availability of antivascular endothelial-derived
growth factors (VEGF) that may be administered
directly into the vitreous, outcomes have signiﬁ-
cantly improved.15
CASE PRESENTATION
A woman aged 52 years, known to have molecu-
larly conﬁrmed SFD (TIMP3 p.Arg204Cys), pre-
sented to the eye clinic with a 3-month history of
reduced vision in the right eye (ﬁgure 1 depicts the
fundus appearance of SFD). Her acuity had fallen
from 6/9 to 6/60 in this eye and funduscopy
revealed a macular lesion suggestive of a CNVM
(ﬁgure 2). The left eye had good vision (6/9) and
no evidence of neovascularisation.
INVESTIGATIONS
OCT imaging identiﬁed hyper-reﬂective material in
the subretinal space which was associated with sub-
retinal and intraretinal ﬂuid (ﬁgure 2). This mate-
rial was presumed to represent a complex of
neovascular tissue; however, the resolution was not
sufﬁcient to directly visualise the retinal vascula-
ture. OCTA imaging was then performed, identify-
ing an abnormal vascular network arising from the
choroid and invading the subretinal space
(CNVM).
DIFFERENTIAL DIAGNOSIS
A differential diagnosis for CNVM is age-related
macular degeneration (AMD). However, our
patient had molecularly conﬁrmed SFD. She had
clinical signs for the same and CNVM is a known
complication of this retinal condition. She is also of
a younger age group compared with patients with
CNVM secondary to AMD.
TREATMENT
After obtaining informed consent and approval of
NHS funding, our patient was treated with two
intravitreal bevacizumab injections, 4 weeks apart.
OUTCOME AND FOLLOW-UP
Treatment was associated with a symptomatic
improvement in vision (6/60 to 6/18). OCT bio-
markers of activity also improved as the ﬂuid seen
on OCT imaging was seen to resolve (ﬁgure 2).
Direct CNVM regression was visible using OCTA
(ﬁgure 3). Our patient will now be monitored to
ensure that the CNVM remains inactive.
Figure 1 Fundus photos of Sorsby fundus dystrophy
(prechoroidal neovascular membrane).
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DISCUSSION
The speciality of ophthalmology is one of the greatest single
users of imaging in medicine. OCTA is the latest iteration of
OCT, a technique that has revolutionised ophthalmic imaging,
and thereby patient care, over the past decade. This report high-
lights the utility of OCTA in patients with IRD, the most
common form of blindness in the working age population in
England and Wales.16 As the current ‘gold standard’ method for
detecting CNVM (fundus ﬂuorescein angiography, FFA) is inva-
sive, time-consuming, costly and associated with a mortality rate
of ∼1:222 000 and other less severe allergic reactions, OCTA
offers signiﬁcant advantages to patients. The high acceptance
rate will enable patients to be imaged at frequent intervals, pre-
viously impossible with FFA. It offers the opportunity to
improve understanding of CNVM formation and regression in
IRD and other forms of retinal disease (including wet AMD—
leading cause of visual loss in the elderly population). It also
provides potentially better directed treatments based on directly
imaging the vascular networks that anti-VEGF therapy aims to
target.
Patient’s perspective
▸ In September 2015, I went to my opticians as I was struggling
to see at work. Photos were taken of my eyes and the optician
said she was not happy about the back of the right eye, she
thought it looked like a hole. As she was aware of my condition
(Sorsby’s dystrophy) and that I was under Moorﬁelds Eye
Hospital, she advised me to send copies to my consultant,
which I did and managed to get an appointment in 3 days time.
▸ When I was seen at Moorﬁelds by Dr A. She informed me that
there was ﬂuid leaking at the back of my eye. We discussed
what could stop it and she advised that an Avastin injection
into the eye could hopefully stop the leakage. All side effects
were listed, but I decided to have it performed. Dr A told me
that a needle had to go into the eye and the vision could be
blurred for a while. I was apprehensive about it but went
ahead. The needle going in felt like a bee sting/needle prick.
I can then remember the ﬂuid looking like bubbles ﬂoating
around the eye, which was very weird. Afterwards, it did feel
painful, which was expected, but not unpleasant. For a few
days after it was quite sore, but when you think, a needle had
gone straight into the eye, it was not surprising. Dr A advised
me that I would probably need 3 injections a month apart and
I was to return the next month.
▸ For the second injection, I was more nervous as I knew what
to expect, the bubbles took longer to go this time. I had
various scans and I was shown how the injections were
helping but I might need another one.
▸ When I returned a month later, again I had further scans,
I was then told that the ﬂuid had stopped leaking and I
would not need a third. I was told initially that the ﬂuid in
the injections would hopefully repair/stop the ﬂuid from
leaking, but in doing so could lead to scarring and could
affect my vision. Having seen the retinal images, I could see
the before and after and was amazed at the difference.
Dr A explained the difference of the images and what the
injections had achieved.
▸ I cannot praise Moorﬁelds enough, you are always treated
with respect, and they explain what is going on and why all
the scans are taken.
▸ I attended the clinic in March 2016 for a follow-up
appointment and was told there was no further ﬂuid leaking,
but along with my condition of Sorsby’s dystrophy and the
Avastin injections, the scarring had affected my central vision
and I could no longer see the letters on the eye chart.
Figure 3 Optical coherence tomography (OCT) angiography images
of the choroidal neovascular membrane pretreatment and
postbevacizumab treatment, with comparison on OCT (automated
segmentation, note the magniﬁcation bars).
Figure 2 (A) Fundus photo and corresponding optical coherence
tomography scan of right eye choroidal neovascular membrane
secondary to Sorsby fundus dystrophy (Pre-treatment).
(B) Corresponding images post Intravitreal Bevacizumab #1.
Learning points
▸ Sorsby fundus dystrophy (SFD) is a cause of premature
macular degeneration and is transmitted in an autosomal
dominant manner.
▸ Optical coherence tomography angiography is a novel
technique useful for visualising choroidal neovascular
membrane (CNVM) and monitoring response to treatment.
▸ It is a safe, non-invasive and quick method as opposed to
conventional fundus ﬂuorescein angiography and the images
are easily comprehensible to patients—which will
revolutionise the way retinovascular diseases are managed.
▸ CNVM secondary to SFD responds well to antivascular
endothelial-derived growth factors therapy.
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